Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA, ImmunityBio's recently approved treatment for non-muscle invasive bladder cancer (NMIBC) Serum Institute of India (SII) will manufacture both standard BCG ("sBCG") and next-generation recombinant BCG ("iBCG"), creating a long-term solution to chronic BCG supply shortage issues Standard BCG (sBCG) from the Serum Institute is currently administered in number of countries worldwide for treatment of NMIBC Recombinant BCG (iBCG) has demonstrated potent immunogenicity with CD8+ and CD4+ stimulation and improved safety compared to standard BCG in clinical trials across Europe. Collaboration will help to...